GH-axis peptides: a primer for patients

If you have come across the phrase "GH-axis support" in a clinic brochure or wellness forum, it refers to using peptides to prompt your pituitary gland to release more growth hormone. Three names come up most often: tesamorelin, CJC-1295, and ipamorelin. This primer covers what each one is, what the published evidence actually shows, and what matters if you are considering raising the subject with a clinician.

How the GH axis works

Growth hormone is released in short pulses from the pituitary gland, prompted mainly by a hypothalamic signal called growth-hormone-releasing hormone (GHRH). Once in circulation, growth hormone travels to the liver and triggers production of insulin-like growth factor 1 (IGF-1), which drives most of the anabolic and metabolic effects attributed to growth hormone: lean-tissue support, fat metabolism, and bone maintenance among them. The peptides in this article work by amplifying that natural signalling chain rather than by introducing synthetic growth hormone directly.

Tesamorelin: the one with a regulatory approval

Tesamorelin is a synthetic analogue of GHRH. In the United States it is sold under the brand name Egrifta and is FDA-approved for one specific indication: reducing excess visceral abdominal fat in adults with HIV who have developed lipodystrophy on antiretroviral therapy. That approval rests on two Phase 3 randomised, placebo-controlled trials. In the pooled analysis (N=806, 26 weeks plus a 26-week extension), tesamorelin 2 mg daily reduced visceral adipose tissue by a mean 24 cm² compared with a 2 cm² rise on placebo; IGF-1 rose 108 ng/ml in the treatment arm versus 7 ng/ml on placebo^[3]. The safety profile over 52 weeks was generally well tolerated, with injection-site reactions, joint discomfort, and fluid retention as the main signals; glucose parameters showed no clinically meaningful change in that population.

Three things to know before any other conversation: tesamorelin has no EU, EEA, or UK marketing authorisation (the European application was withdrawn in 2012 after the EMA raised concerns about the clinical significance of the fat reduction and IGF-1 elevation safety signals). The approved evidence base is specific to HIV-associated lipodystrophy, not general body composition. And off-label use in healthy adults has not been tested in any randomised efficacy trial.

CJC-1295: early-phase data, no completed efficacy trial

CJC-1295 is a modified GHRH analogue with an albumin-binding linker that extends its half-life from roughly two minutes to five to eight days^[1]. The key feature is that it stimulates sustained GH and IGF-1 elevation while preserving the pulsatile secretory pattern the pituitary normally uses^[2]. A single injection in healthy adults produced two- to tenfold GH increases for six days or more and raised IGF-1 between 1.5- and 3-fold for nine to eleven days in the Teichman 2006 trial; the compound was described as safe and well tolerated at 30 and 60 mcg/kg^[1].

That study and a companion pharmacology paper represent the full extent of published controlled human data. ConjuChem, the developer, did not advance CJC-1295 to a Phase 2 or Phase 3 efficacy trial for any indication. The compound is not approved anywhere, sits on the WADA prohibited list under section S2, and is widely sold in the grey market, often mislabelled or confused with the shorter-acting MOD-GRF(1-29) variant that lacks the albumin linker. The CJC-1295 grey-market risks page covers the supply-chain picture in more detail.

Ipamorelin: selective, studied in pharmacokinetics, no efficacy trial

Ipamorelin works differently. Rather than mimicking GHRH, it binds the ghrelin receptor (GHS-R1a) to stimulate GH release. Its distinguishing feature in the 1998 preclinical characterisation was selectivity: it triggered GH release without significantly elevating cortisol or ACTH, even at doses 200-fold above its GH-effective threshold^[4]. That selectivity profile separated it from older growth-hormone-releasing peptides like GHRP-2 and GHRP-6.

The published human data is pharmacokinetic rather than therapeutic. A 1999 study in eight healthy male volunteers dosed ipamorelin intravenously across five escalating doses and modelled the relationship between plasma concentration and GH output. The terminal half-life was approximately two hours; GH peaked at 0.67 hours post-dose. The study confirmed that the compound reaches the pituitary and triggers GH release in humans^[5]. It was not designed to demonstrate efficacy for any clinical endpoint, and no Phase 2 or Phase 3 trial of ipamorelin for a GH-axis indication has been published since. The ipamorelin grey-market risks page covers what the absence of a regulated supply means in practice.

A 2026 review of injectable peptide therapy for orthopaedic and sports medicine noted that GH secretagogues including ipamorelin and CJC-1295 have shown effects in animal models but that "significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made"^[6]. A separate 2026 orthopaedic narrative review placed ipamorelin and CJC-1295 among agents that activate IGF-1 signalling and satellite cell repair in preclinical work, while also noting the absence of clinical trial data^[7].

What the evidence gap means for you

Showing that a peptide raises IGF-1 in blood is not the same as showing it produces a health benefit. Clinical benefit requires a controlled trial measuring a specific outcome in a specific population. Tesamorelin has that, for one indication. CJC-1295 and ipamorelin do not, for any indication. That gap does not make them certainly harmless or certainly harmful; it means we genuinely do not know what the chronic risk-benefit balance looks like in healthy adults. Our deeper GH-axis evidence grading piece walks through that hierarchy in full.

Long-term elevation of IGF-1 in people without documented GH deficiency is not well-studied for safety. Pathological GH excess, as seen in acromegaly, is associated with joint problems, insulin resistance, and soft-tissue changes. Whether the IGF-1 increases from CJC-1295 or ipamorelin produce similar effects over years of use is an open question with no published answer. If you want to explore the regulatory picture by country, the details are on the tesamorelin regulation page, the CJC-1295 regulation page, and the ipamorelin regulation page.

What we don't know yet

No multi-year safety study of CJC-1295 or ipamorelin in healthy adults has been published. The tesamorelin extension data covers 52 weeks in an HIV-positive population on antiretroviral therapy, which is not the population most likely to encounter these compounds through grey-market or compounding channels. Optimal dosing outside the approved tesamorelin indication, the long-term oncologic risk of sustained IGF-1 elevation in non-deficient adults, and the clinical significance of the hormonal effects seen in early-phase studies all remain uncharacterised.